Abeona Therapeutics’ (NASDAQ:ABEO) “Buy” Rating Reaffirmed at Cantor Fitzgerald

Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating reissued by Cantor Fitzgerald in a research note issued on Friday, October 6th. They currently have a $21.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 25.75% from the stock’s current price.

Other equities analysts have also issued reports about the company. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research note on Monday, September 18th. Maxim Group set a $17.00 price target on Abeona Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 16th. BidaskClub lowered Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 27th. Zacks Investment Research lowered Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th. Finally, Jefferies Group LLC restated a “buy” rating and set a $22.00 price target on shares of Abeona Therapeutics in a research note on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Abeona Therapeutics currently has an average rating of “Buy” and an average price target of $22.56.

Shares of Abeona Therapeutics (NASDAQ ABEO) opened at 16.70 on Friday. The company’s 50-day moving average price is $15.53 and its 200 day moving average price is $8.77. The stock’s market cap is $672.79 million. Abeona Therapeutics has a 1-year low of $4.05 and a 1-year high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. The business had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.21 million. Equities analysts forecast that Abeona Therapeutics will post ($0.70) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Abeona Therapeutics’ (NASDAQ:ABEO) “Buy” Rating Reaffirmed at Cantor Fitzgerald” was first posted by BBNS and is owned by of BBNS. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/abeona-therapeutics-inc-abeo-stock-rating-reaffirmed-by-cantor-fitzgerald/1697999.html.

A number of large investors have recently made changes to their positions in ABEO. Family Management Corp bought a new position in Abeona Therapeutics in the first quarter valued at approximately $120,000. State of Wisconsin Investment Board bought a new position in Abeona Therapeutics in the second quarter valued at approximately $122,000. Rhumbline Advisers bought a new position in Abeona Therapeutics in the second quarter valued at approximately $190,000. Bank of New York Mellon Corp increased its stake in Abeona Therapeutics by 125.8% in the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock valued at $210,000 after acquiring an additional 23,358 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. bought a new position in Abeona Therapeutics in the second quarter valued at approximately $264,000. 38.38% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.